Ulisse Biomed S.p.A. (UBM.MI)
EUR 0.78
(0.0%)
EUR 0.78
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -2.37 Million EUR | -204.59% |
| 2022 | -1.54 Million EUR | -134.8% |
| 2021 | -657.75 Thousand EUR | -428.88% |
| 2020 | 200 Thousand EUR | 128.57% |
| 2019 | -700 Thousand EUR | -1424.86% |
| 2018 | -45.9 Thousand EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -202.08 Thousand EUR | 0.0% |
| 2024 Q1 | -202.08 Thousand EUR | 61.17% |
| 2023 FY | -4.7 Million EUR | -204.59% |
| 2023 Q3 | -520.43 Thousand EUR | 40.58% |
| 2023 Q4 | -520.43 Thousand EUR | 0.0% |
| 2023 Q2 | -875.89 Thousand EUR | -244.72% |
| 2023 Q1 | -254.09 Thousand EUR | 69.59% |
| 2022 Q2 | -708.76 Thousand EUR | -225.82% |
| 2022 FY | -1.54 Million EUR | -134.8% |
| 2022 Q3 | -229.85 Thousand EUR | 67.57% |
| 2022 Q1 | -217.53 Thousand EUR | 64.0% |
| 2022 Q4 | -835.62 Thousand EUR | -263.54% |
| 2021 FY | -657.75 Thousand EUR | -428.88% |
| 2021 Q1 | 13.13 Thousand EUR | -94.85% |
| 2021 Q2 | -53.44 Thousand EUR | -506.89% |
| 2021 Q3 | -145.84 Thousand EUR | -172.87% |
| 2021 Q4 | -604.3 Thousand EUR | -314.34% |
| 2020 Q2 | -216.56 Thousand EUR | -691.47% |
| 2020 FY | 200 Thousand EUR | 128.57% |
| 2020 Q3 | 180.47 Thousand EUR | 183.34% |
| 2020 Q1 | -27.36 Thousand EUR | 0.0% |
| 2020 Q4 | 254.86 Thousand EUR | 41.22% |
| 2019 FY | -700 Thousand EUR | -1424.86% |
| 2018 FY | -45.9 Thousand EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ARTERRA BIOSCIENCE | -157.83 Thousand EUR | -1405.658% |
| Philogen S.p.A. | 5.66 Million EUR | 141.92% |